GAITHERSBURG, Maryland (Reuters) - Pfizer Inc.'s pain reliever Celebrex should be approved for treating rheumatoid arthritis in children despite uncertainty about the risks of long-term use, U.S.

Back in 2004, a popular arthritis drug called Vioxx was pulled off the market when studies showed daily long-term use could increase the risk of heart attack, stroke and death. “This was one of the ...

Testing Celebrex in children gave Pfizer, the world’s biggest drugmaker, six more months of patent protection, an incentive the FDA grants to companies to develop pediatric treatments. The safety of ...

NEW YORK (Reuters) - Ads for Pfizer Inc.'s Celebrex arthritis drug are set to splash across U.S. television screens on Monday after more than a two-year hiatus, with an unusual upfront focus on its ...

The Food and Drug Administration on Friday issued a warning on the popular arthritis drug Celebrex after studies showed that high doses of the drug increases the chance of heart attacks and strokes.

NEW ORLEANS — A new study gives some reassurance to arthritis sufferers who want pain relief but are worried about side effects. It finds that Celebrex, a drug similar to ones withdrawn 12 years ago ...

A new use for a common painkiller. A medication prescribed to treat pain appears to have the power to keep cancer at bay. Celebrex is an anti-inflammatory used to alleviate symptoms of arthritis, ...

Patients taking the popular painkiller Celebrex should consider switching to other drugs, and those who stay on it should use the lowest possible dose, the FDA said Friday after new safety concerns ...

An FDA panel found Celebrex does not cause a greater risk of heart attacks and strokes compared to two other commonly prescribed painkillers, NPR reports. Here are five things to know. 1. Celecoxib is ...

PHILADELPHIA - New research suggests that top-selling pain reliever Celebrex does not carry the same heart attack risk as Vioxx, a similar drug pulled from the market in September because of safety ...